Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 13, 2017, Pages 3479-3484

  Baradaran Heravi, Alireza ^a   Niesser, Jürgen ^a   Balgi, Aruna D ^a   Choi, Kunho ^a   Zimmerman, Carla ^a   South, Andrew P ^b   Anderson, Hilary J ^a   Strynadka, Natalie C ^a   Bally, Marcel B ^c   Roberge, Michel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cancer; Gentamicin B1; Nonsense mutation; Premature stop codon readthrough; Rare genetic diseases

Indexed keywords

COLLAGEN TYPE 7; DYSTROPHIN; GARAMINE; GENTAMICIN; GENTAMICIN A; GENTAMICIN B; GENTAMICIN B1; GENTAMICIN C1; GENTAMICIN C1A; GENTAMICIN C2; GENTAMICIN C2A; GENTAMICIN C2B; PROTEIN P53; SISOMICIN; SWI/SNF RELATED MATRIX ASSOCIATED ACTIN DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY B MEMBER 1; TRANSFER RNA; UNCLASSIFIED DRUG; AMINOPEPTIDASE; ANTIINFECTIVE AGENT; DIPEPTIDYL PEPTIDASE; DMD PROTEIN, HUMAN; SERINE PROTEINASE; TRIPEPTIDYL-PEPTIDASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICODON; ARTICLE; CODON; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; FLUORESCENCE IMAGING; GENETIC DISORDER; KERATINOCYTE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NONSENSE MUTATION; PHARMACOGENETICS; PRIORITY JOURNAL; RIBOSOME; RNA CONFORMATION; STOP CODON; TUMOR XENOGRAFT; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; MUTATION; TUMOR CELL LINE;

AMINOPEPTIDASES; ANTI-BACTERIAL AGENTS; CELL LINE, TUMOR; CODON, NONSENSE; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DYSTROPHIN; GENTAMICINS; HUMANS; MUTATION; SERINE PROTEASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85016417255     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1620982114     Document Type: TB

References (30)

1. Mort M, Ivanov D, Cooper DN, Chuzhanova NA (2008) A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 29(8):1037-1047.
2. Electronic Medicines Compendium (2017) Gentamicin 10mg/ml solution for injection or infusion. Available at https://www.medicines.org.uk/emc/medicine/32933. Accessed March 3, 2017.
3. Malik V, et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67(6):771-780.
4. Clancy JP, et al. (2001) Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163(7):1683-1692.
5. Linde L, Kerem B (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 24(11):552-563.
6. Stypulkowska K, Blazewicz A, Fijalek Z, Sarna K (2010) Determination of gentamicin sulphate composition and related substances in pharmaceutical preparations by LC with charged aerosol detection. Chromatographia 72(11-12):1225-1229.
7. Baradaran-Heravi A, et al. (2016) Novel small molecules potentiate premature termination codon readthrough by aminoglycosides. Nucleic Acids Res 44(14):6583-6598.
8. Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E (2015) Translational readthrough potential of natural termination codons in eucaryotes: The impact of RNA sequence. RNA Biol 12(9):950-958.
9. Brown A, Shao S, Murray J, Hegde RS, Ramakrishnan V (2015) Structural basis for stop codon recognition in eukaryotes. Nature 524(7566):493-496.
10. Ogle JM, et al. (2001) Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292(5518):897-902.
11. Budkevich TV, et al. (2014) Regulation of the mammalian elongation cycle by subunit rolling: A eukaryotic-specific ribosome rearrangement. Cell 158(1):121-131.
12. Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V (2002) Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell 111(5):721-732.
13. Garreau de Loubresse N, et al. (2014) Structural basis for the inhibition of the eukaryotic ribosome. Nature 513(7519):517-522.
14. Floquet C, Hatin I, Rousset J-P, Bidou L (2012) Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. PLoS Genet 8(3):e1002608.
15. Wang CS, et al. (2000) Establishment and characterization of a new cell line derived from a human primary breast carcinoma. Cancer Genet Cytogenet 120(1):58-72.
16. Roy B, et al. (2016) Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci USA 113(44):12508-12513.
17. Keeling KM, Xue X, Gunn G, Bedwell DM (2014) Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet 15:371-394.
18. Arribere JA, et al. (2016) Translation readthrough mitigation. Nature 534(7609):719-723.
19. Welch EM, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447(7140):87-91.
20. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4(3):435-447.
21. Pronk S, et al. (2013) GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29(7):845-854.
22. Tou WI, Chang S-S, Lee C-C, Chen CY-C (2013) Drug design for neuropathic pain regulation from traditional Chinese medicine. Sci Rep 3:844.
23. Aghdam EM, Hejazi ME, Hejazi MS, Barzegar A (2014) Riboswitches as potential targets for aminoglycosides compared with rRNA molecules: In silico studies. J Microb Biochem Technol S9:002.
24. Pourreyron C, et al. (2014) High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion. Br J Dermatol 170(6):1256-1265.
25. Pettersen EF, et al. (2004) UCSF Chimera: A visualization system for exploratory research and analysis. J Comput Chem 25(13):1605-1612.
26. Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: A fast force field generation tool for small organic molecules. J Comput Chem 32(11):2359-2368.
27. Bjelkmar P, Larsson P, Cuendet MA, Hess B, Lindahl E (2010) Implementation of the CHARMM force field in GROMACS: Analysis of protein stability effects from correction maps, virtual interaction sites, and water models. J Chem Theory Comput 6(2):459-466.
28. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926-935.
29. Darden TA, Pedersen LG (1993) Molecular modeling: An experimental tool. Environ Health Perspect 101(5):410-412.
30. Hess B, Bekker H, Berendsen HJC, Fraaije JEGM (1997) LINCS: A linear constraint solver for molecular simulations. J Comput Chem 18:1463-1472